Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sagopilone + acetyl-l-carnitine + prednisone
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Sagopilone + acetyl-l-carnitine + prednisone is a combination regimen investigated primarily for the treatment of advanced ovarian cancer and castration-resistant prostate cancer. Sagopilone is a fully synthetic epothilone that acts as a microtubule-stabilizing agent, disrupting cell division and inducing apoptosis in cancer cells. Acetyl-L-carnitine is a dietary supplement and neuroprotective agent studied for its potential to prevent or reduce chemotherapy-induced peripheral neuropathy, particularly from microtubule-targeting agents like sagopilone. Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, commonly used as supportive care in oncology regimens. The combination has been evaluated in phase II clinical trials; while acetyl-L-carnitine did not significantly reduce overall incidence of peripheral neuropathy compared to placebo, it was associated with lower rates of severe neuropathy in some patient subgroups[1][4][5][6].
- Other names
- ALClevocarnitineprednisolone
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))CRAT (Carnitine O-acetyltransferase)
Beyond the preview
Go deeper on sagopilone + acetyl-l-carnitine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sagopilone + acetyl-l-carnitine + prednisone.